Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Shaw

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Clinical Therapeutics|July 20, 2010
Lack of support for cost-utility analysis in the health care reform law: a case of ignorance or political posturing?James W Shaw
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 23, 2002
Economic evaluations of olanzapine and risperidoneJames W Shaw
Clinical Therapeutics|July 1, 2011
Use of patient versus population preferences in economic evaluations of health care interventionsJames W Shaw
JAMA|December 14, 2006
Association between migraine and cardiovascular disease in womenWilliam B Young, James W Shaw
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Mapping EQ-5D-3L to EQ-5D-5LBen A van Hout, James W Shaw
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 4, 2012
The effect of chronic conditions on stated preferences for healthA Simon Pickard, Rima Tawk, James W Shaw
Journal of Patient-Reported Outcomes|September 4, 2018
Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse eventsRebecca M Speck, William R Lenderking, James W Shaw
Medical Care|February 24, 2005
US valuation of the EQ-5D health states: development and testing of the D1 valuation modelJames W Shaw, Jeffrey A Johnson, Stephen Joel Coons
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 12, 2021
General population normative data for the EQ-5D-3L in the five largest European economiesMathieu F Janssen, A Simon Pickard, James W Shaw
Journal of Cancer Survivorship : Research and Practice|January 18, 2020
The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of lifeRebekah Park, James W Shaw, Alix Korn, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Clinical Therapeutics|July 20, 2010
Lack of support for cost-utility analysis in the health care reform law: a case of ignorance or political posturing?James W Shaw
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 23, 2002
Economic evaluations of olanzapine and risperidoneJames W Shaw
Clinical Therapeutics|July 1, 2011
Use of patient versus population preferences in economic evaluations of health care interventionsJames W Shaw
JAMA|December 14, 2006
Association between migraine and cardiovascular disease in womenWilliam B Young, James W Shaw
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Mapping EQ-5D-3L to EQ-5D-5LBen A van Hout, James W Shaw
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 4, 2012
The effect of chronic conditions on stated preferences for healthA Simon Pickard, Rima Tawk, James W Shaw
Journal of Patient-Reported Outcomes|September 4, 2018
Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse eventsRebecca M Speck, William R Lenderking, James W Shaw
Medical Care|February 24, 2005
US valuation of the EQ-5D health states: development and testing of the D1 valuation modelJames W Shaw, Jeffrey A Johnson, Stephen Joel Coons
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 12, 2021
General population normative data for the EQ-5D-3L in the five largest European economiesMathieu F Janssen, A Simon Pickard, James W Shaw
Journal of Cancer Survivorship : Research and Practice|January 18, 2020
The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of lifeRebekah Park, James W Shaw, Alix Korn, et al.
Pageof 6